<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130832</url>
  </required_header>
  <id_info>
    <org_study_id>V260-014</org_study_id>
    <secondary_id>2005_030</secondary_id>
    <nct_id>NCT00130832</nct_id>
  </id_info>
  <brief_title>Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)</brief_title>
  <official_title>Safety and Immunogenicity of Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The study is being conducted to demonstrate that vaccine to prevent gastroenteritis due to
      rotavirus may be administered concomitantly with oral polio vaccine (OPV) without impairing
      the safety or immunogenicity of either vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3</measure>
    <time_frame>Approximately 42 days Postdose 3</time_frame>
    <description>GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)</measure>
    <time_frame>Approximately 42 days Postdose 3</time_frame>
    <description>GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered</measure>
    <time_frame>Approximately 42 days Postdose 3</time_frame>
    <description>Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">735</enrollment>
  <condition>Rotavirus Infections</condition>
  <condition>Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RotaTeq and OPV concomitantly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RotaTeq and OPV on staggered schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus Vaccine, Live, Oral, Pentavalent</intervention_name>
    <description>Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Oral Poliovirus Vaccine (OPV)</intervention_name>
    <description>Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Oral Poliovirus Vaccine (OPV) (staggered)</intervention_name>
    <description>Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants in good health

        Exclusion Criteria:

          -  Previous administration of any oral poliovirus vaccine (OPV) and rotavirus vaccine

          -  Receipt of inactivated poliovirus vaccine (IPV) prior to the first dose of either
             study vaccine, or at any time during the course of the study

          -  Any condition resulting in depressed immunity

          -  Any allergy to any vaccine component as stated in the package circulars

          -  Allergies to polymyxin B, neomycin or any other antibiotics

          -  Receipt of intramuscular, oral, or intravenous corticosteroid treatment

          -  History of congenital abdominal disorders, intussusception, or abdominal surgery;
             clinical evidence of active gastrointestinal illness

          -  History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to
             thrive

          -  Prior receipt of a blood transfusion or blood products, including immunoglobulin

          -  Fever, with a rectal temperature of ≥38.1°C (≥ 100.5°F) at the time of immunization

          -  Infants residing in a household with an immunocompromised person
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
    <country>Costa Rica</country>
    <country>Guatemala</country>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Ciarlet M, Sani-Grosso R, Yuan G, Liu GF, Heaton PM, Gottesdiener KM, Arredondo JL, Schödel F. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J. 2008 Oct;27(10):874-80. doi: 10.1097/INF.0b013e3181782780.</citation>
    <PMID>18756184</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2005</study_first_posted>
  <results_first_submitted>August 7, 2009</results_first_submitted>
  <results_first_submitted_qc>August 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2010</results_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment occurred at 9 study sites in Mexico, Costa Rica, Guatemala, and Brazil from 19-Oct-2005 (first subject in) to 06-Jan-2006 (last subject randomized).</recruitment_details>
      <pre_assignment_details>Excluded from randomization were subjects with history of congenital abdominal disorders, intussusception, or abdominal surgery; history of known prior rotavirus disease, chronic diarrhea, or failure to thrive, clinical evidence of active gastrointestinal illness and those with fever, a rectal temperature ≥38.1°C (≥100.5°F) at time of immunization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RotaTeq and Oral Poliovirus (OPV) Concomitantly</title>
          <description>Subjects (Sbjs) in Group 1 who received 3 concomitant doses of RotaTeq™ and OPV ≥56 to ≤84 days (8 to 10 weeks) apart</description>
        </group>
        <group group_id="P2">
          <title>RotaTeq and Oral Poliovirus (OPV) Staggered</title>
          <description>Subjects in Group 2, who received RotaTeq™ first followed by OPV between ≥14 to ≤28 days (2 to 4 weeks) later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="372"/>
                <participants group_id="P2" count="363"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="356">Those who received all 3 doses of concomitant RotaTeq™/ OPV with blood draw ~42 days postdose 3</participants>
                <participants group_id="P2" count="346">Those who received all 3 doses; last 2 blood draws ~42 days postdose 3 of RotaTeq™ and postdose OPV</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RotaTeq and Oral Poliovirus (OPV) Concomitantly</title>
          <description>Subjects (Sbjs) in Group 1 who received 3 concomitant doses of RotaTeq™ and OPV ≥56 to ≤84 days (8 to 10 weeks) apart</description>
        </group>
        <group group_id="B2">
          <title>RotaTeq and Oral Poliovirus (OPV) Staggered</title>
          <description>Subjects in Group 2, who received RotaTeq™ first followed by OPV between ≥14 to ≤28 days (2 to 4 weeks) later</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="372"/>
            <count group_id="B2" value="363"/>
            <count group_id="B3" value="735"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>5 Weeks of Age and Under</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 12 Weeks of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Over 12 Weeks of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3</title>
        <description>GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.</description>
        <time_frame>Approximately 42 days Postdose 3</time_frame>
        <population>The primary immunogenicity analyses were based on evaluable per-protocol subjects who received all scheduled doses, were not protocol violators, and had valid assay values.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq and Oral Poliovirus (OPV) Concomitantly</title>
            <description>Subjects (Sbjs) in Group 1 who received 3 concomitant doses of RotaTeq™ and OPV ≥56 to ≤84 days (8 to 10 weeks) apart</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq and Oral Poliovirus (OPV) Staggered</title>
            <description>Subjects in Group 2, who received RotaTeq™ first followed by OPV between ≥14 to ≤28 days (2 to 4 weeks) later</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer(s) of Poliovirus Types 1, 2, and 3, Measured Approximately 42 Days Postdose 3</title>
          <description>GMT of poliovirus type 1, 2, and 3, measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.</description>
          <population>The primary immunogenicity analyses were based on evaluable per-protocol subjects who received all scheduled doses, were not protocol violators, and had valid assay values.</population>
          <units>Geometric Mean Titer (GMT)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antibody Responses to Poliovirus Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="888.0" lower_limit="752.8" upper_limit="1047"/>
                    <measurement group_id="O2" value="1139" lower_limit="969.1" upper_limit="1340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody Responses to Poliovirus Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="814.9" lower_limit="720.7" upper_limit="921.4"/>
                    <measurement group_id="O2" value="814.5" lower_limit="707.4" upper_limit="937.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody Responses to Poliovirus Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.6" lower_limit="201.9" upper_limit="270.2"/>
                    <measurement group_id="O2" value="269.2" lower_limit="230.6" upper_limit="314.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Seroprotection rate (proportion of subjects who achieve the seroprotection criteria: neutralizing antibody titers [NA] ≥1:8) for poliovirus type 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority criterion is that the lower limit of the 2-sided 95% confidence interval of the proportion difference (concomitant group minus staggered group) for subjects who achieve neutralizing antibody titers [NA] ≥1:8 greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen's</method>
            <method_desc>Comparing seroprotection rate difference with the non-inferiority margin of 0.10 with Miettinen and Nurminen's method.</method_desc>
            <param_type>Seroprotection Rate Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Seroprotection rate (proportion of subjects who achieve the seroprotection criteria: neutralizing antibody titers [NA] ≥1:8) for poliovirus type 2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority criterion is that the lower limit of the 2-sided 95% confidence interval of the proportion difference (concomitant group minus staggered group) for subjects who achieve neutralizing antibody titers [NA] ≥1:8 greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen's</method>
            <method_desc>Comparing seroprotection rate difference with the non-inferiority margin of 0.10 with Miettinen and Nurminen's method.</method_desc>
            <param_type>Seroprotection Rate Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Seroprotection rate (proportion of subjects who achieve the seroprotection criteria: neutralizing antibody titers [NA] ≥1:8) for poliovirus type 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority criterion is that the lower limit of the 2-sided 95% confidence interval of the proportion difference (concomitant group minus staggered group) for subjects who achieve neutralizing antibody titers [NA] ≥1:8 greater than -10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen's</method>
            <method_desc>Comparing seroprotection rate difference with the non-inferiority margin of 0.10 with Miettinen and Nurminen's method.</method_desc>
            <param_type>Seroprotection Rate Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)</title>
        <description>GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered</description>
        <time_frame>Approximately 42 days Postdose 3</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq and Oral Poliovirus (OPV) Concomitantly</title>
            <description>Subjects (Sbjs) in Group 1 who received 3 concomitant doses of RotaTeq™ and OPV ≥56 to ≤84 days (8 to 10 weeks) apart</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq and Oral Poliovirus (OPV) Staggered</title>
            <description>Subjects in Group 2, who received RotaTeq™ first followed by OPV between ≥14 to ≤28 days (2 to 4 weeks) later</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of Serum Anti-rotavirus Immunoglobulin A (IgA)</title>
          <description>GMT of serum anti-rotavirus IgA measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered</description>
          <population>Per Protocol Population</population>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.9" lower_limit="126.4" upper_limit="189.9"/>
                    <measurement group_id="O2" value="292.7" lower_limit="248.6" upper_limit="344.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority criterion is that the lower limit of the 2-sided 95% confidence interval of the GMT ratio (concomitant group over staggered group) greater than 0.50.</non_inferiority_desc>
            <p_value>0.277</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA model on log titer of serum anti-rotavirus IgA</method_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>non-inferiority criterion is that the lower limit of the 2-sided 95% confidence interval of the proportion difference (concomitant group minus staggered group) for subjects who achieve 3-fold rise in serum anti-rotavirus IgA greater than -10%.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Miettinen and Nurminen's</method>
            <method_desc>Comparing percentage difference with the non-inferiority margin of 10 percentage point with Miettinen and Nurminen's method.</method_desc>
            <param_type>Percentage Point Difference</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
            <estimate_desc>Percentage point difference (concomitant – staggered)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered</title>
        <description>Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.</description>
        <time_frame>Approximately 42 days Postdose 3</time_frame>
        <population>Per Protocol Population
For serotype G4 the RotaTeq and Oral Poliovirus (OPV) concomitantly group N = 350</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq and Oral Poliovirus (OPV) Concomitantly</title>
            <description>Subjects (Sbjs) in Group 1 who received 3 concomitant doses of RotaTeq™ and OPV ≥56 to ≤84 days (8 to 10 weeks) apart</description>
          </group>
          <group group_id="O2">
            <title>RotaTeq and Oral Poliovirus (OPV) Staggered</title>
            <description>Subjects in Group 2, who received RotaTeq™ first followed by OPV between ≥14 to ≤28 days (2 to 4 weeks) later</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of RotaTeq™ as Measured by Serum Neutralizing Antibody [SNA] Responses to Rotavirus Serotypes G1, G2, G3, G4, and P1A When Administered With OPV Concomitantly or Staggered</title>
          <description>Rotavirus SNA response to serotypes G1, G2, G3, G4, and P1A measured at postdose 3 in subjects receiving RotaTeq™ and OPV concomitantly compared to staggered.</description>
          <population>Per Protocol Population
For serotype G4 the RotaTeq and Oral Poliovirus (OPV) concomitantly group N = 350</population>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SNA responses to rotavirus serotypes G1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.8" lower_limit="106.7" upper_limit="148.2"/>
                    <measurement group_id="O2" value="182.6" lower_limit="158.2" upper_limit="210.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SNA responses to rotavirus serotypes G2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="22.9" upper_limit="32.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="25.9" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SNA responses to rotavirus serotypes G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="18.4" upper_limit="24.32"/>
                    <measurement group_id="O2" value="22.5" lower_limit="19.4" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SNA responses to rotavirus serotypes G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="50.2" upper_limit="68.1"/>
                    <measurement group_id="O2" value="74.5" lower_limit="64.3" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SNA responses to rotavirus serotypes P1A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="71.97" upper_limit="99.8"/>
                    <measurement group_id="O2" value="131.4" lower_limit="112.6" upper_limit="153.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects in this study were followed for all adverse experiences, for 14 days following each study vaccination.</time_frame>
      <desc>The number of subjects listed in the Adverse Event tables is the number of subjects who received study treatment.
Although a subject may have had two or more clinical adverse experiences the patient is counted only once in a category. The same subject may appear in different categories.</desc>
      <group_list>
        <group group_id="E1">
          <title>RotaTeq and Oral Poliovirus (OPV) Concomitantly</title>
          <description>Subjects (Sbjs) in Group 1 who received 3 concomitant doses of RotaTeq™ and OPV ≥56 to ≤84 days (8 to 10 weeks) apart</description>
        </group>
        <group group_id="E2">
          <title>RotaTeq and Oral Poliovirus (OPV) Staggered</title>
          <description>Subjects in Group 2, who received RotaTeq™ first followed by OPV between ≥14 to ≤28 days (2 to 4 weeks) later</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="342" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="325" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="202" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="366"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

